ACH Accendra Health, Inc.

bearish · high conviction track record → $3.33 -0.19 (-5.4%)
Get emailed when ACH changes direction
Mkt Cap $255M 52wk $1.84 - $9.55 Earnings 2026-05-07 48d ago
Insider buying: $39,776,920 bought by 17 insiders (30d)
Est. revisions: -8.1% (1 up, 1 down in 30d)
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -1.0)

Factor Model

net -1.0 2.6 / 10
Est. Revisions
-0.5
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
+0.0
Narrative Gap
+0.0

$300M revenue headwind coming, but pivoting to core care

Watch: Track 2026 H1 results closely. The company expects only 40% of annual EBITDA in the first half, which means a dramatic back-half recovery is baked into guidance — miss that and the narrative inverts fast.

Accendra Health grew revenue 3% in 2025 to $2.8B but faces a cliff: a major commercial payer exit will slice $300M from top line in 2026. The company is shedding non-core assets to focus on home-based care brands Byram and Apria — a structural shift that management believes positions the business better long-term. Q4 EBITDA fell 12% year-over-year to $90M, signaling momentum weakening before the payer loss hits.

This isn't a typical slowdown — it's a forced restructuring into a core business that's presumably higher-margin but smaller. Management is betting that losing $300M in revenue (roughly 11% of total) while focusing on home care actually improves profitability, but the near-term math is brutal: 2026 revenue is guided to $2.55–$2.65B (down 9–10%) with EBITDA falling to $335–$355M (down 11–13%). If that pivot doesn't deliver margin accretion or new growth, this is a value destruction story.

Evidence

9d ago Insider buy by COLISEUM CAPITAL MANAGEMENT, L.L.C. (ACH): $27,386,158
9d ago Insider buy by COLISEUM CAPITAL MANAGEMENT, L.L.C. (ACH): $4,291,218
9d ago Insider buy by COLISEUM CAPITAL MANAGEMENT, L.L.C. (ACH): $8,099,544
Fundamentals & Data ▾
Accendra Health, Inc. Healthcare · Medical Distribution
Mkt Cap
$255M
Beta
1.26
52w Range
$1.84 - $9.55
Short Interest
7.5M 12.19%
Days to Cover
8.8 -8%
Technicals downtrend
from 52w Hi
-5.4%
1w return
+5.7%
Insiders
selling 0B / 8S
EPS Estimate
$-0.10 -8.1% 30d 1up / 1dn
Est. Dispersion
140% 5 analysts
Analyst Target
$3 $2 - $5
Options P/C
0.04
Insider Cluster
strong sell 1B / 6S
Financials
Revenue
$709M -74% YoY
FCF
$59M
Gross Margin
46%
Op Margin
7%
Momentum: decelerating
Recent Filings & Data
insider trade 44
net buying · $1,868,058 sold · $39,776,920 bought
17 insiders · 44 transactions (30d)
Recent transactions
BERNOCCHI PERRY A · award
LEON JONATHAN A · award
GALLOWAY HEATH H. · award
LONG ANDREW G. · other
COLISEUM CAPITAL MANAGEMENT, L.L.C. · buy · $8,099,544
BECK MARK A. · award
KLINE TERESA L. · award
JOHNSON-MILLS RITA · award
HENKEL ROBERT J · award
KLEMASH STEPHEN W. · award
GARDNER-SMITH KENNETH · award
ROLLINS CARISSA · award
COLISEUM CAPITAL MANAGEMENT, L.L.C. · buy · $4,291,218
COLISEUM CAPITAL MANAGEMENT, L.L.C. · buy · $27,386,158
BERNOCCHI PERRY A · award
PESICKA EDWARD A · award
LOWRY MICHAEL WAYNE · award
LONG ANDREW G. · award
LEON JONATHAN A · award
SARKAR SNEHASHISH · award
GALLOWAY HEATH H. · award
STONE JENNIFER A · award
LEON JONATHAN A · sell · $62,433
SARKAR SNEHASHISH · sell · $25,194
LEON JONATHAN A · award
LEON JONATHAN A · sell · $118,725
LONG ANDREW G. · other
LOWRY MICHAEL WAYNE · award
LEON JONATHAN A · award
BERNOCCHI PERRY A · sell · $350,003
BECK MARK A. · sell · $161,184
SARKAR SNEHASHISH · sell · $172,854
BRUNI ALEXANDER J · sell · $187,688
STONE JENNIFER A · award
GALLOWAY HEATH H. · sell · $80,097
BECK MARK A. · award
KLINE TERESA L. · award
JOHNSON-MILLS RITA · award
HENKEL ROBERT J · award
KLEMASH STEPHEN W. · award
GARDNER-SMITH KENNETH · award
ROLLINS CARISSA · award
BERNOCCHI PERRY A · sell · $585,680
LEON JONATHAN A · sell · $124,200
5 signals · latest 9d ago

Get alerted when ACH changes direction

We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.